Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: beta-1,3-D-glucan synthase inhibitors - Merck/SCYNEXIS

Next Previous
X
Search
Drug Profile

Research programme: beta-1,3-D-glucan synthase inhibitors - Merck/SCYNEXIS

Alternative Names: Antifungals - Merck/SCYNEXIS; Enfumafungin derivatives - Merck/SCYNEXIS

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; SCYNEXIS
  • Class Echinocandins; Glycosides; Triterpenes
  • Mechanism of Action Beta-1,3-D glucan synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Mycoses
  • Discontinued Bacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in USA (PO)
  • 15 Sep 2009 Pharmacodynamics and Antimicrobial data from a preclinical trial in mycosis presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009) ,,
  • 05 Oct 2006 No development reported - Preclinical for Bacterial infections in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top